Combined Synopsis/SolicitationPosted Apr 22, 2026·Original deadline passed (May 2). See latest amendment for current deadline.

Human putative humanin peptide (MT-RNR2) ELISA kits

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO

Stage
Open solicitation
NAICS
325414
Value
Not stated
Solicitation
75N98026Q00243
Set-aside
No Set aside used
PSC
6505
Place
MD, USA
Contact
John Johnson (johnsonjr@mail.nih.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 75N98026Q00243 in this department, oldest first.

Early notice
None posted
Solicitation
  • Apr 22, 2026 · this notice
    Combined Synopsis/Solicitation
Award
Not yet. Expected award: Any day (median passed). Typical range May 8, 2026 to Jul 14, 2026; middle May 20, 2026.
Measured from 139 past solicitations at National Institutes of Health that later posted an award (middle half of cases, counted from Apr 22, 2026).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Decide bid or no bid before the response deadline.
  • Look at the past winners for likely competitors and teaming partners.
  • Follow the opportunity to hear about amendments and the award.

What the notice says

COMBINED SYNOPSIS / SOLICITATION-COMPETITIVE Title: Human putative humanin peptide (MT-RNR2) ELISA kits This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a separate written solicitation will not be issued. The solicitation number is 75N98026Q00243 and the solicitation is issued as request for quotation (RFQ). Simplified Acquisition Procedure… (show all)

s; and FAR Part 12�Acquisition of Commercial Items and is not expected to exceed the simplified acquisition threshold. A fixed-price type of purchase order is contemplated for this requirement. The National Institute of Aging (NIA), Investigators in the HANDLS study require data on circulating humanin (MT-RNR2) levels to support an ongoing longitudinal study. This data will expand our current research on examining how circulating factors play a role in age-related chronic disease. Humanin has anti-apoptotic, metabolic and neuroprotective properties and also has been associated with lifespan. It is important to quantitatively measure serum levels of humanin in HANDLS participants to understand the role of this hormone in aging, and age-related chronic disease, including type 2 diabetes. The government requires specific ELISA kits because the government has specific expertise, equipment and resources to perform the work using these kits at our Institute. Attachment 1 � Purchase Description for additional details. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2025-05, dated 08-07-2025. The North American Industry Classification System (NAICS) Code for this procurement is 325414� Biological Product (Except Diagnostic) Manufacturing. Line Items: Through this procurement NIA anticipates a single award, firm fixed price purchase order for a total of forty-nine (49) Human Putative humanin peptide(MT-RNR2) ELISA Kits. (Lowest Price Technically Acceptable) as described in Attachment 1 � Purchase Description Below is a table that contains the line item numbers and description of the brand name or equal requirement for the anticipated award. Line No. Description 1 Human Putative humanin peptide(MT-RNR2) ELISA. SIZE 96T. QTY of 49. Description Requirement: Humanin (MT-RNR2) is a small, mitochondria-derived peptide that has attracted significant scientific interest due to its cytoprotective and anti-apoptotic properties. Humanin has been associated with aging and age-related chronic diseases including type 2 diabetes, neurodegenerative diseases and cardiovascular disease. To gain insight into its role in these processes in human cohorts, we will quantitatively measure levels of circulating humanin using ELISA kits. We will measure human humanin from serum from HANDLS participants. Serum samples from HANDLS participants are precious and limited quantities are available. Therefore, only a limited amount (<50 ul) can be used for this ongoing longitudinal study. We previously measured humanin using an ELISA kit (POTS# 24-012790) in a pilot study of 176 HANDLS participants. The government requires additional kits to expand upon this initial pilot study and to support an ongoing longitudinal study. For continuity of research and comparability of results, we need to use the same kit (CSB-EL015084HU) to measure humanin in additional HANDLS participants Salient characteristics: Human Humanin ELISA kit o-ELISA technology -96 well format -one kit assays humanin in 96 samples (including standards) -measure humanin from human serum -sensitivity to measure humanin at <7 pg/ml -required volume of serum to be <50 ul -compatibility to read absorbance on a SpectraMax M2 Microplate Reader -for continuity of research we need to compare our new data to our previous results using the Human Putative humanin peptide (MT-RNR2) ELISA kits (CSB-EL015084HU). -for the validity of the scientific research, data generated will need to be directly compared to those previously published in human aging cohorts. The human putative humanin peptide (MT-RNR2) (MT-RNR2) ELISA kits (CSB-EL015084HU) was used to assay humanin in human aging cohorts. Therefore for the validity and direct comparability of our results to our previous results and those previously published, the government requires this same kit to assay the levels of humanin. Period of Performance 12 months from the date of the award. Option Quantities N/A Shipping Instructions NIH/NIDA 251 Bayview Blvd STE 100 BRC Bldg. RM 06C232 Baltimore MD 21224 Delivery Within 2 weeks from receipt and acceptance of award. Payment Net 30 Statutory Authority: This notice is a Combined Synopsis/Solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 �Streamlined Procedures for Evaluation and solicitation for commercial Items,� as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. Closing Statement: Responses to this notice must include sufficient information to establish the interested parties� bona-fide capabilities of providing the product. The response shall include: the unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following: brand name requirements salient characteristics, price, and delivery. By submitting a quote in response to this solicitation, vendor is accepting the following terms and conditions: The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (SEP 2023) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (OCT 2025) FAR 52.204-7 System for Award Management (NOV 2024) (Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure FAR 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (NOV 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements � Representation (JAN 2017) 52.204�26 Covered Telecommunications Equipment or Services-Representation(OCT 2020) FAR 52.211-6 Brand Name or Equal (AUG 1999) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (NOV 2023) FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (JAN 2025) (see Attachement 2) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (MAR 2023) FAR 52.204-13 System for Award Management Maintenance (OCT 2018) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (DEC 2015) FAR 52.252-2 -- Clauses Incorporated by Reference. (FEB 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will mak

Who won similar work

3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6505.

Single-winner award sizes (3): middle half $82K to $470K, median $137K; range $28K to $804K.

WinnerAwardsValueLast
VECTOR BIOMED INC.1$804KDec 2, 2024
PACIFIC BIOSCIENCES OF CALIFORNIA, INC · $PACB · $159.3M1$137KNov 19, 2024
10X GENOMICS, INC. · $TXG · $616.9M1$28KDec 20, 2024

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

Investor context
  • $PACB reported $159.3M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing
  • $TXG reported $616.9M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards
  • Dec 20, 202410X GENOMICS, INC.$28K65--Xenium Add On KitMateriality: <0.01% of $TXG revenue (Low) SEC
  • Dec 2, 2024VECTOR BIOMED INC.$804KServices for the Production and Stability Testing of Clinical Grade Lentiviral VectorNo listed company matched (Materiality N/A)
  • Nov 19, 2024PACIFIC BIOSCIENCES OF CALIFORNIA, INC$137K65--Revio SPRQ reagent kitMateriality: 0.09% of $PACB revenue (Low) SEC

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
  • 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 2 of the past winners are listed companies
  • 0 insider buys and 5 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.